GH Research (GHRS) Other financing activities (2020 - 2023)
GH Research's (GHRS) quarterly Other financing activities came in at -$8.2 million in Q2 2023, down 52.37% year-on-year from -$17.2 million in Q2 2022, and down 107.79% quarter-over-quarter from $105.1 million in Q1 2023.
GH Research (GHRS) Other financing activities (2020 - 2023) Analysis & Trends
GH Research's Other financing activities history runs 4 years deep, the most recent figure standing at -$8.2 million for Q2 2023.
- On a quarterly basis, Other financing activities fell 52.37% year-over-year to -$8.2 million in Q2 2023; TTM through Jun 2023 was $108.3 million, a 59.19% decrease from a year earlier, with the FY2022 full-year figure at $276.8 million, down 10.49% from the prior year.
- Other financing activities declined to -$8.2 million in Q2 2023 per GHRS's latest filing, from $105.1 million in the prior quarter.
- Across five years, Other financing activities topped out at $304.6 million in Q2 2021 and bottomed at -$8.4 million in Q3 2022.
- The 4-year median for Other financing activities is $4.9 million (2020), against an average of $68.8 million.
- Biggest YoY gain for Other financing activities was 5816.74% in 2022; the steepest drop was 101.76% in 2022.
- Year by year, Other financing activities stood at $5.2 million in 2020, then soared by 5795.57% to $304.6 million in 2021, then tumbled by 93.49% to $19.8 million in 2022, then plunged by 141.27% to -$8.2 million in 2023.
- Per Business Quant, the three latest GHRS Other financing activities figures stand at -$8.2 million (Q2 2023), $105.1 million (Q1 2023), and $19.8 million (Q4 2022).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | GH Research | 1.65 Bn | 1.65 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -8.19 Mn |
| Jun 30, 2023 | -8.19 Mn |
| Mar 31, 2023 | 105.08 Mn |
| Mar 31, 2023 | 105.08 Mn |
| Dec 31, 2022 | 19.84 Mn |
| Dec 31, 2022 | 19.84 Mn |
| Sep 30, 2022 | -8.44 Mn |
| Sep 30, 2022 | -8.44 Mn |
| Jun 30, 2022 | -5.37 Mn |
| Jun 30, 2022 | -5.37 Mn |
| Mar 31, 2022 | 270.75 Mn |
| Mar 31, 2022 | 270.75 Mn |
| Jun 30, 2021 | 304.62 Mn |
| Jun 30, 2021 | 304.62 Mn |
| Mar 31, 2021 | 4.58 Mn |
| Mar 31, 2021 | 4.58 Mn |
| Dec 31, 2020 | 5.17 Mn |
| Dec 31, 2020 | 5.17 Mn |
| Sep 30, 2020 | -51,000.00 |
| Sep 30, 2020 | -51,000.00 |